Clinical trial
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18)…
NCT00365716 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00365716 |
|---|---|
| Title | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) |
| Official title | A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections, Genital Diseases, Female |
| Intervention type | Biological |
| Interventions | Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Vaccine 20/40/40/20, 18) L1 VLP Vaccine 40/40/40/40, 18) L1 VLP Vaccine 80/80/40/80, Placebo (mcg) (Aluminum Adjuvant)225, Placebo (mcg) (Aluminum Adjuvant) 450 |
| Enrollment | 1,158 |
| Start date | May 1, 2000 |
| Primary completion | May 1, 2004 |
| Completion | Sep 1, 2009 |
| First posted | Aug 17, 2006 |
| Last update posted | Oct 7, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: